TY - JOUR
T1 - Survival in squamous cell carcinoma of the oral cavity
T2 - Differences between pT4 N0 and other stage IVA categories
AU - Liao, Chun Ta
AU - Chang, Joseph Tung Chieh
AU - Wang, Hung Ming
AU - Ng, Shu Hang
AU - Hsueh, Chuen
AU - Lee, Li Yu
AU - Lin, Chih Hung
AU - Chen, I. How
AU - Huang, Shiang Fu
AU - Cheng, Ann Joy
AU - Yen, Tzu Chen
PY - 2007/8/1
Y1 - 2007/8/1
N2 - BACKGROUND. According to the American Joint Commission on Cancer (AJCC, 5th edition) classification system, pT4 N0 oral cavity squamous cell carcinoma (OSCC) qualifies for stage IVA status, with its implied poor prognosis. However, preliminary observations suggested that patients with pT4 N0 OSCC might have better survival than other stage IVA categories. The authors sought to identify accurate prognosticators in patients with stage III/IVA OSCC. METHODS. The authors retrospectively reviewed 513 consecutive patients with stage III/IVA OSCC who were undergoing radical surgery. Survival was plotted by Kaplan-Meier analysis. RESULTS. One hundred seventy-eight patients were in stage III, and 335 were in stage IVA. The 335 stage IVA patients were divided into pT4 N0 (n = 105) and pT4 N1/TAny N2 (NO pT4 N0 M0, n = 230). By univariate analysis, 5-year neck control rates (P < .0001), distant metastases (P < .0001), disease-free survival rates (P < .0001), and overall survival rates (P < .0001) were significantly different in pT4 N0 compared with NO pT4 N0 patients. No significant difference in survival between pT4 N0 stage IVA and pstage III could be shown. Multivariate analysis for overall survival demonstrated that the following factors were independently associated with pT4 N0: tumor depth ≥35 mm, vessel invasion, lymph invasion, and perineural invasion. In contrast, tumor depth ≥25 mm, treatment with surgery alone, poor differentiation, extracapsular spread, and pathological nodal metastases (≥8 lymph nodes) were independent predictors of overall survival in NO pT4 N0. CONCLUSIONS. In patients with stage IVA OSCC (AJCC, 1997), the survival rates for pT4 N0 are better than those for NO pT4 N0 and similar to those of patients with pstage III.
AB - BACKGROUND. According to the American Joint Commission on Cancer (AJCC, 5th edition) classification system, pT4 N0 oral cavity squamous cell carcinoma (OSCC) qualifies for stage IVA status, with its implied poor prognosis. However, preliminary observations suggested that patients with pT4 N0 OSCC might have better survival than other stage IVA categories. The authors sought to identify accurate prognosticators in patients with stage III/IVA OSCC. METHODS. The authors retrospectively reviewed 513 consecutive patients with stage III/IVA OSCC who were undergoing radical surgery. Survival was plotted by Kaplan-Meier analysis. RESULTS. One hundred seventy-eight patients were in stage III, and 335 were in stage IVA. The 335 stage IVA patients were divided into pT4 N0 (n = 105) and pT4 N1/TAny N2 (NO pT4 N0 M0, n = 230). By univariate analysis, 5-year neck control rates (P < .0001), distant metastases (P < .0001), disease-free survival rates (P < .0001), and overall survival rates (P < .0001) were significantly different in pT4 N0 compared with NO pT4 N0 patients. No significant difference in survival between pT4 N0 stage IVA and pstage III could be shown. Multivariate analysis for overall survival demonstrated that the following factors were independently associated with pT4 N0: tumor depth ≥35 mm, vessel invasion, lymph invasion, and perineural invasion. In contrast, tumor depth ≥25 mm, treatment with surgery alone, poor differentiation, extracapsular spread, and pathological nodal metastases (≥8 lymph nodes) were independent predictors of overall survival in NO pT4 N0. CONCLUSIONS. In patients with stage IVA OSCC (AJCC, 1997), the survival rates for pT4 N0 are better than those for NO pT4 N0 and similar to those of patients with pstage III.
KW - Prognosis
KW - Squamous cell carcinoma
KW - Stage IVA
UR - http://www.scopus.com/inward/record.url?scp=34547098016&partnerID=8YFLogxK
U2 - 10.1002/cncr.22814
DO - 10.1002/cncr.22814
M3 - 文章
C2 - 17577219
AN - SCOPUS:34547098016
SN - 0008-543X
VL - 110
SP - 564
EP - 571
JO - Cancer
JF - Cancer
IS - 3
ER -